11:55 AM EDT, 10/09/2025 (MT Newswires) -- Novo Nordisk ( NVO ) Chief Executive Officer Mike Doustdar said he is poised to face calculated risks on acquisitions to stay competitive and regain market share in weight-loss treatment, Bloomberg News reported Thursday, citing an interview.

"You need to be able to have an eye on who else is out there, who has possibly invented something above and beyond what we could do," Doustdar said, according to the report.

The company can't "shy away in taking some additional risks," the CEO said, according to the report.

On Thursday, Novo agreed to buy Akero Therapeutics ( AKRO ) for up to $5.2 billion in cash.

Novo didn't immediately reply to a request for comment from MT Newswires.

Novo shares fell 1.3% in recent Thursday trading, and Akero jumped 17%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 58.82, Change: -0.79, Percent Change: -1.33